Siga Technologies Inc (SIGA) Stock Price & Analysis
Siga Technologies Inc (SIGA) fell 1.27% to USD 3.11 as of July 26, 2026 at 11:30 UTC, according to Nexqual real-time market data.
SIGA last closed at USD 3.15; the session ranged USD 3.03–3.18 on volume of 869,183 shares. Market capitalization is $223.06M, with a 52-week range of USD 3.03–9.62 (NGM). Source: Nexqual, July 26, 2026 at 11:30 UTC.
Key Statistics (as of July 26, 2026 at 11:30 UTC)
| Price | USD 3.11 |
|---|---|
| Change | ▼ 1.27% (down) |
| Previous Close | USD 3.15 |
| Open | USD 3.14 |
| Day Range | USD 3.03 – 3.18 |
| 52-Week Range | USD 3.03 – 9.62 |
| Volume | 869,183 shares |
| Market Cap | $223.06M |
| Exchange | NGM |
Technical Analysis (SIGA)
Nexqual's technical model rates SIGA "SELL" based on 3 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 11:30 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 27.42 (oversold) |
| vs SMA50 | Below (USD 4.06) |
| MACD | -0.23 (negative) |
Analyst Ratings (SIGA)
Wall Street analysts rate SIGA "None", per Nexqual as of July 26, 2026 at 11:30 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 0 / 0 / 0 |
Earnings (SIGA)
| Next Earnings Date | 2026-08-04 |
|---|
Source: Nexqual, July 26, 2026 at 11:30 UTC.
Financials & Fundamentals (SIGA)
| Total Revenue | $93.78M |
|---|---|
| Revenue Growth (YoY) | -11.30% |
| Gross Margin | +43.56% |
| Operating Margin | -85.24% |
| Profit Margin | +21.58% |
| ROE | +11.00% |
| Debt / Equity | 0.4 |
| Current Ratio | 3.25 |
| Total Cash | $145.56M |
| Total Debt | $601,016 |
| Free Cash Flow | $59.44M |
Source: Nexqual, July 26, 2026 at 11:30 UTC.
Financial Health Score (SIGA)
Nexqual rates Siga Technologies Inc's overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 11:30 UTC.
| Growth | Critical — Revenue -32% YoY (annual), sharp decline |
|---|---|
| Profitability | Mixed — Gross margin 44%, operating -85% |
| Balance Sheet | Strong — $146M cash, no debt |
| Cash Flow | Strong — FCF $59M, 63% margin |
| Efficiency | Mixed — ROE 11%, ROA 5.5% |
Ownership (SIGA)
| Insider Ownership | +42.80% |
|---|---|
| Institutional Ownership | +49.89% |
| Shares Outstanding | 71.72M |
| Float | 41.01M |
| Short % of Float | +8.48% |
Source: Nexqual, July 26, 2026 at 11:30 UTC.
Leadership (SIGA)
Siga Technologies Inc is led by Diem Nguyen (age 53), CEO & Director, per Nexqual as of July 26, 2026 at 11:30 UTC.
| CEO & Director | Diem Nguyen (age 53) |
|---|---|
| Executive VP, CFO & Secretary | Daniel J. Luckshire (age 54) |
| Executive VP & Chief Scientific Officer | Dennis E. Hruby (age 73) |
Major Backers & Investors (SIGA)
Notable institutional backers of Siga Technologies Inc include American Century Companies Inc, AltraVue Capital, LLC, Arrowstreet Capital, Limited Partnership, according to Nexqual as of July 26, 2026 at 11:30 UTC.
Active Investors
| Investor | Stake |
|---|---|
| American Century Companies Inc | 3.28% |
| AltraVue Capital, LLC | 3% |
| Arrowstreet Capital, Limited Partnership | 1.89% |
| AQR Capital Management, LLC | 1.51% |
| First Wilshire Securities Management Inc | 1.1% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.87% |
| Vanguard Group | 4.19% |
| Dimensional Fund Advisors | 3.86% |
| Geode Capital | 1.63% |
| State Street | 1.25% |
Source: Nexqual, July 26, 2026 at 11:30 UTC.
From Siga Technologies Inc's Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- Expiration dates for pending patent applications, if granted, will fall between 2031 and 2037.   FDA regulations require that patented drugs be sold under brand names that comply with various regulations.
- Upon completion of such clinical testing, a company typically submits a New Drug Application ("NDA") to the FDA that summarizes the results and observations of the drug during the clinical testing.
Partnerships
- As of December 31, 2025, there are exercised options for the following activities: payments up to $450.2 million for the manufacture and delivery of up to 1.5 million courses of oral TPOXX®; payments up to $76.8 million for the manufacture of courses of IV FDP; payments of up to approximately $3.6 million to fund post-marketing activities for IV TPOXX®; and payments of up to $14.6 million for funding of post-marketing activities for oral TPOXX®.
- The Company's agreement with Microsize's predecessor was amended on January 11, 2019.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GOVX | GeoVax Labs, Inc. | USD 0.73 | ▼ 21.9% |
| VERU | Veru Inc. | USD 2.25 | ▼ 0.44% |
| EBS | Emergent BioSolutions Inc. | USD 7.26 | ▼ 4.22% |
| BVNRY | Bavarian Nordic A/S | USD 8.76 | ▼ 4.79% |
| RIGL | Rigel Pharmaceuticals, Inc. | USD 36.74 | ▼ 2.8% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 11:30 UTC. This page is informational and not investment advice.